Objective : To describe the clinical response to gabapentin in the treatment of neuropathic and musculoskeletal pain and to determine if a correlation exists between dose and pain response in a variety of painful disorders. To our knowledge, this is the first report of gabapentin used for neuropathic pain from carpal tunnel syndrome (CTS), thoracic outlet syndrome, plexopathies, and femoral neuropathy; and musculoskeletal pain from osteoarthritis, low back pain (LBP), tension headaches, and rotator cuff tears.
neuropathic and/or musculoskeletal pain. Spearman rank correlation was used to test for a relationship between gabapentin dose and pain reduction. There were 19 males and 10 females; ages ranged from 20 to 76 years with a mean age of 47.
Results : At least a 30 percent reduction in pain was reported by 25 of 29 patients. Gabapentin was tolerated well with few side effects.
Conclusion: This case series suggests that gabapentin is beneficial in the treatment of neuropathic and musculoskeletal pain. Double-blind, placebo-controlled studies appear to be warranted to investigate the use of gabapentin in musculoskeletal pain. Key Words: Gabapentin (GBP)&mdash;Antiepileptic drugs (AEDs)&mdash;Pain&mdash;Reflex sympathetic dystrophy (RSD)&mdash;Dejerine-Roussy syndrome (DRS)&mdash;Spinal cord injury (SCI) Management nf pain often is difficult and frustrating tor physicians. Tlll current medical treatment ai.ailable for pain frequently is frauuhr with unwanted side effects, may be addictive, and often is 1111sllccesstlll. Insufficient drug therapies, coupted with evidence llt ~;.1LWl~~t:IlCIrI~S (GBP) benign nature, warrants wide consideration of GBP fur treatment of pain syndromes. Gabapentin shows promise in treating neuropathic pain with very few side effects ( I ~. In this case series, GBP also appears to he helpful in treating musculoskelet,,1 pain.
Gabapenrin, which was approved hy the U.S. Food and Drug Administration (FL~A) in Fchruary 1994, is effective as an ê.1lld-on therapy tor refractory partial seizures (2). The effective dose of gabapentin is 900 to 1800 mg per day in divided dnses, hut doses up to 3600 mg per day have been wet) tolerated (2), Gahapentin is not appreciably hound to plasma protein and therefore has almost no interaction with other drugs except antacids, which reduce the bioavailability of the drug and necessitate an increase in the GBP dose (2). GBP is not metabolized by the liver. It is eliminated unchanged from the systemic circulation by renal excretion. There is no requirement to monitor drug concentrations during treatment (3). Gabapentin has a relatively low toxicity and side effect profile.
GBP was synthesized as a gamma-aminobutyric acid (GABA) analogue, but it does not interact with GABA receptors (3) (4) (5) . Its binding occurs in the outer layers of the nencortex, hippncampus, and other brain locations, but the reccptors and biochemical function remain undiscovered (4, 6) . GBP may induce pain reduction by exerting a modulating effect at neuronal receptor sites, augmenting or inhilJitiiig thc release of ncurotransmitters as dopaminc, serotonin, and norepinephrine (5) (6) (7) . A spinal site of action alw is suggested (8) . O13P may potentiate morphine-induced analgesia and hal<>pcriLl<>I catalepsy (9) and may increase GABA concentrations in the human brain ( 10) .
The mechanism of action for gabapenrin is unknown. Anecdotal reports indicate that gabapentin is an elective analgesic for reflex sympathetic dystrophy (RSD) (11) (12) (13) (14) and (~fher neuropathic pain syndromes (1, (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) , Wider clinical use of gabapenrin is warranted for management of protean pain states. Hence this case series is presented.
Methods
Patients seen from May 1995 to October 1997 in a freestanding rural Missouri neurorehabilitation center, who were suffering from moderate to severe pain, were ottered a tri;ll of treatment ,,.ith gabapentiii..All patients were included without regard to type of pain, length of time pain was present, or whether pain treatment had been tried previously. Consent was obtained from 29 patients after informing them of pofentia) risks and benefits of treatment. Patients graded their pain using a verhal pain intensity scale of 0 to 10. )abe)ing (1 as no pain, 1 to 3 as mild pain, 4 to 6 as moderate pain, 7 to 9 as severe pain, and 10 as the worst measurable pain, The patients' ages ranged from 20 to 76 years with a mean age of 47. To test for a correlation between dose of gabapentin and pain response, the Spearman rank test was used.
Subjects included spinal cord injury (SCI) patients with neuropathic pain, CTS, and osteoarthritis; stroke patients with reflex sympathetic dystrophy (RSD) and Dejerine-Roussy syndrome (DRS); multitrauma patients with thoracic outlet syndrome, tension headaches, and plexopathies (brachial and l llllllhlls~l~l-Ml); and patients with LBP, hct;r<it<>pic ossification, Guillain Barre syndrome, and neuropathy. Patient characteristics are sum-inari=eLi in Table 1 .
Results
Twenty-nine patients with neuropathic and/or musculoskeletal pain were started on an increasing dose of GBP until a reduction in pain was achieved or side effects occurred. Satisfactory relief was obtained for all types of pain in 25 of 29 patients (86 pcl-cent). Results arc summarized in Table 2 .
Pain R~~cltcctiun
There was a statistically significant correlation (Spearman correlation coefficient) between ORP dose and percent pain reduction (corr = 0.47, p walm for test d =cro correlation = 0.035). Twcnty-fiw patients reported at least a 30 percent reduction in pain, and two of these patients rcpc7rtc~ a 90 percent reduction in pain (cases #8 and #10). Four patients reported no rclicf of pain (cases ~11, -~12, =16, and =2C ). A nonresponding traumatic brain injury (TBI) patient expected immediate relief from pain associated with tension headaches (case =11 ) and aborted the trial after nine days and achieving a dose of 900 mg TID. One RSD patient (case =12), discontinued GhP hecause of constant fatigue and uizzincss after two weeks on a dose of 300 mg BID. Another nonre~plH1ding patient with chl-Otllc LBP for 25 5 years (c;~se=16), discontinued GBP (900 mg TID) at hospital discharge. The final nonresponding patient (casc =26), with diabetic mononeuropathies (sciatic and femoral) did not respond on 600 I11g TID after two weeks and discontinued GBP on thc advice of his primary care physician.
DOS~'
In this report the effective dose of GBP for pain relief ranged from 300 mg BID (600 m~/day) to 900 I11g TID (2700 iiig/diiy). Most patients were able to tolerate dose increases of 200 to 300 mg daily. Those who obtained some pain c~mtrc7l with GBP were able to achieve further pain reduction if they Could tc7lerate a higher dc7se. It appeared that dosing could not be spaced more than 10 to 12 hours apart in order to maintain the same amount of pain control.
Side Effects
Thirty-four percent of the patients reported no side effects. The most commonly experienced side effects were fatigue, drowsiness, dizziness, nausea, slurred speech, and diarrhea. Four patients (cases ~1, #7, #12 and -=27) discontinued GBP because of side effects, although they reported good pain reduction. Side effects appeared to resolve in 2 to 30 days (mean 13 days). The shortest time to response was one day, whereas rhe lungest response time was 21 days (mean 8 days). There are accounts of patients reporting complete pain relief after taking the first GBP capsute ( 12, 13) . This was not seen in this case series. There was no correlation between response time and thc amount of pain reduction.
When GBP was discontinued, pain appeared to return to baseline in 6 to 10 hours.
Discussion
Gabapentin's mechanism of action in seizure control or pain reduction remains to be defined. GBP is believed to possess a unique, as yet unidentified, receptor in brain tissuc (9) . GBP increascs concentration of brain GABA and modulates other neurotransmitters known to be important for pain control (7, 8, 10) .
GBP was chosen for pain management in this case series because of its tow inherent toxicity and lack of drug interactions. GBP may be particularly considered as a treatment of pain in the elderly who are receiving multiple medications. There is no requirement to monitor drug concentration during therapy and routine laboratory testing is unnecessary (3) . The dose should be adjusted on the basis of clinical signs and symptoms (3) .
Side effects are similar to those of other anfiepileptic drugs (AEDs), i.e., dizziness, ataxia, fatigue, tremor, somnolence, diplopia, nausea, and vomiting. AEDs have been advocated in the management of refractory neuropathic pain. For example, carbamazepine is the drug of choice for trigeminal neuralgia (24) . One of the major limitations of AEDs is the high incidence of side effects. GBP has a much lower incidence of side effects than other AEDs (1) .
The majority (86 percent) of patients treated with GBP for pain in this case series obtained some relief of pain. GBP has shown promise in the treatment of neu-ropathic pain such as RSD (14) , postherpetic neuralgia (22) , radiation myelopathy (23) , trigeminal neuralgia (16, 17) , Dejerine-Roussy syndrome (DRS) (20) , erythromelalgia (18, 19) , restless legs syndrome (6) , migraine headache ( 21 ), post-polio syndrome ( 1 5 ) and even GBS (25, 26) . Although thc pain intensity instrument used in this report may not accurately reflect pain response hecause of a number of complex issues related to the validity of such instruments, this case series suggests that GBP may also he helpful in managing musculoskeletal pain.
In conclusion, this is the largest case series reporting on GBP for pain thus far. To our knowledge, this is the first report of GBP in neuropathic pain caused by CTS, thoracic outlet syndrome, plexopathies and femoral neuropathy ; for musculoskeletal pain syndromes such as osteoarthritis, LBP, tension hcadaches, and rotator cuff tears; as well as the first reported cases of GBP failure in the management of pain. Although this exploratory preuminary report suggests that a dose-response effect exists between GBP in both musculoskeletal and neuropathic pain syndromes, further research using randomized controlled methods would be useful to help clinicians identify subscts of patients with painful conditions that might respond to GBP.
